AASTOCKS Financial News

HSI¹	25,668.03	+137.75	259.69B
HSCEI¹	8,531.58	+32.85	62.84B

Back Zoom + Zoom - Block Traded

SBP GROUP (01177.HK) Bemarituzumab Combined With Anlotinib Approved for New Indication
2026-08-09 19:06:26
SBP GROUP (01177.HK) announced that Bemarituzumab injection (brand name: Andewei), a Category 1 innovative drug independently developed by its subsidiary Chia Tai Tianqing, in combination with chemotherapy followed by anlotinib hydrochloride capsules (brand name: Fucowei), has received marketing approval from China's National Medical Products Administration for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer. This marks the 12th approved indication for anlotinib and the sixth approved indication for Bemarituzumab. (de/d)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

(1) HK Indices are real time

Home|RT Quote|Market|News|Indices
Feedback

View: Mobile|Desktop
Lang: 繁|简|EN

Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.